DUBLIN, IRELAND AND LONDON, UK = / ACCESS Newswire / December 8, 2025 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation today ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
Please provide your email address to receive an email when new articles are posted on . Prior trials established the role of haploidentical BMT for severe aplastic anemia. Two trials underway have the ...
The FDA has approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia (SAA). Specifically, omidubicel is ...
DUBLIN, IE AND LONDON, UK / ACCESS Newswire / December 5, 2025 / Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a leader in cell therapy innovation announces that it ...
In early-onset severe hemolytic disease of the fetus and newborn (HDFN), transplacental transfer of maternal antierythrocyte IgG alloantibodies causes fetal anemia that leads to the use of high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results